1. Home
  2. TKNO vs LUNG Comparison

TKNO vs LUNG Comparison

Compare TKNO & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TKNO
  • LUNG
  • Stock Information
  • Founded
  • TKNO 1996
  • LUNG 1995
  • Country
  • TKNO United States
  • LUNG United States
  • Employees
  • TKNO N/A
  • LUNG N/A
  • Industry
  • TKNO Medicinal Chemicals and Botanical Products
  • LUNG Industrial Specialties
  • Sector
  • TKNO Health Care
  • LUNG Health Care
  • Exchange
  • TKNO Nasdaq
  • LUNG Nasdaq
  • Market Cap
  • TKNO 244.7M
  • LUNG 248.0M
  • IPO Year
  • TKNO 2021
  • LUNG 2020
  • Fundamental
  • Price
  • TKNO $5.06
  • LUNG $6.82
  • Analyst Decision
  • TKNO Buy
  • LUNG Strong Buy
  • Analyst Count
  • TKNO 2
  • LUNG 7
  • Target Price
  • TKNO $5.00
  • LUNG $13.71
  • AVG Volume (30 Days)
  • TKNO 122.0K
  • LUNG 217.5K
  • Earning Date
  • TKNO 11-07-2024
  • LUNG 10-28-2024
  • Dividend Yield
  • TKNO N/A
  • LUNG N/A
  • EPS Growth
  • TKNO N/A
  • LUNG N/A
  • EPS
  • TKNO N/A
  • LUNG N/A
  • Revenue
  • TKNO $34,940,000.00
  • LUNG $76,583,000.00
  • Revenue This Year
  • TKNO $3.22
  • LUNG $22.73
  • Revenue Next Year
  • TKNO $14.88
  • LUNG $19.02
  • P/E Ratio
  • TKNO N/A
  • LUNG N/A
  • Revenue Growth
  • TKNO N/A
  • LUNG 26.26
  • 52 Week Low
  • TKNO $1.16
  • LUNG $5.46
  • 52 Week High
  • TKNO $5.46
  • LUNG $14.84
  • Technical
  • Relative Strength Index (RSI)
  • TKNO 57.83
  • LUNG 37.18
  • Support Level
  • TKNO $4.68
  • LUNG $6.56
  • Resistance Level
  • TKNO $5.21
  • LUNG $7.47
  • Average True Range (ATR)
  • TKNO 0.37
  • LUNG 0.37
  • MACD
  • TKNO 0.00
  • LUNG -0.21
  • Stochastic Oscillator
  • TKNO 75.51
  • LUNG 11.93

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: